APA (7th ed.) Citation

Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., . . . Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. The lancet. Oncology, 23(8), . https://doi.org/10.1016/S1470-2045(22)00335-7

Chicago Style (17th ed.) Citation

Budde, Lihua E., et al. "Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-arm, Multicentre, Phase 2 Study." The Lancet. Oncology 23, no. 8 (2022). https://doi.org/10.1016/S1470-2045(22)00335-7.

MLA (9th ed.) Citation

Budde, Lihua E., et al. "Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-arm, Multicentre, Phase 2 Study." The Lancet. Oncology, vol. 23, no. 8, 2022, https://doi.org/10.1016/S1470-2045(22)00335-7.